OneRobotics (Shenzhen) Co., Ltd. (6600)

Overview

Founded in 1990 and headquartered in Shanghai, the People's Republic of China, SciClone Pharmaceuticals (Holdings) Limited stands as a monumental figure in the biopharmaceutical industry, particularly known for its vigorous engagement in the development and commercialization of pharmaceutical products. The company primarily operates within the therapeutic areas of oncology and severe infection, serving medical needs not just in Mainland China but also on an international scale. Through its innovative approach and dedication, SciClone Pharmaceuticals has carved a niche for itself, focusing on treatments that promise a better quality of life for patients suffering from chronic diseases.

Products and Services

SciClone Pharmaceuticals boasts an impressive portfolio of proprietary and in-licensed pharmaceutical products designed to combat a variety of severe health conditions:

• Zadaxin: As the company's crown jewel, Zadaxin is used primarily for the treatment of chronic hepatitis B, symbolizing the company's commitment to fighting pervasive liver diseases.
• Zometa: This product is vital for patients undergoing the struggle with multiple myeloma and those with documented bone metastases from solid tumors, including the treatment of hypercalcemia of malignancy.
• DANYELZA: Specifically indicated for the treatment of relapsed/refractory high-risk neuroblastoma, DANYELZA illustrates SciClone’s focus on tackling some of the most challenging pediatric cancers.
• Vibativ: Addressing the critical area of hospital-acquired and ventilator-associated bacterial pneumonia, Vibativ stands out as a key solution in the company's portfolio for severe bacterial infections.
• Omburtamab: Targeted for the treatment of CNS/leptomeningeal metastasis from neuroblastoma, Omburtamab emphasizes SciClone’s innovation in addressing cancer's impact on the nervous system.
• RRx-001: This small molecule immunotherapeutic is in development for the treatment of solid tumors, showcasing the company's venture into advanced cancer therapy paradigms.
• PEN-866: A drug conjugate focused on solid tumors, PEN-866 represents the company's efforts in targeted cancer therapies.
• HSP90-PI3K SMDC: Another candidate for the treatment of solid tumors, emphasizing SciClone's commitment to expanding its arsenal against cancer.
• PT-112: Aimed at treating late-stage prostate cancer and cholangiocarcinoma, PT-112 is an example of SciClone’s dedication to addressing less common but equally devastating cancers.
• ABTL-0812: This product is focused on treating cancers such as endometrial, lung, and pancreatic, further showcasing the company's broad approach to oncology.

All these products highlight SciClone Pharmaceuticals' strategy of addressing a wide range of severe health issues through an extensive distribution network that encompasses hospitals and pharmacies, thus ensuring that their solutions are accessible to patients in need across China and beyond.